MetaCap

Sol-Gel Technologies Ltd. (SLGL)

NASDAQ: SLGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD

55.17+1.09 (+2.02%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SLGL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$180.63M
EPS (TTM)
-$5.22
52-week range
34.47 – 97.97
Day range
51.81 – 56.16
Volume / Avg
24.36K / 47.38K
Beta
—

52-week range

$34.47$97.97

SLGL stock today

Shares of Sol-Gel Technologies (SLGL) finished higher on Nov 20 at $55.17, a gain of 2.02% or $1.09 per share, versus the S&P 500's 3.70% decline. At this level, SLGL sits in the middle of its 52-week range of $34.47 to $97.97: 43.7% below the high, set on Mar 3, 2026 and 60.1% above the low. SLGL is up 30.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 50.5%.

Sol-Gel Technologies has posted a net loss over the last twelve months (EPS of -$5.22), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Sol-Gel Technologies

Company profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Moshe Arkin
Headquarters
Ness Ziona
Employees
28
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Sol-Gel Technologies generated $19.4 million in revenue, up 68.0% from fiscal 2024, its 2nd consecutive year of revenue growth. Sol-Gel Technologies reported a net loss of $6.1 million, compared with a loss of $10.6 million a year earlier. Operating margin was -38.9%.

Sol-Gel Technologies annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$19.39M$11.54M$1.55M$3.88M$31.27M
Growth+68.04%+642.47%-59.98%-87.58%+256.54%
Net income$-6.13M$-10.58M$-27.24M$-14.92M$3.22M
EPS (diluted)$-2.19$-3.79$-10.01$-0.65$0.14

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$155.50+181.86%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $110.00High $201.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-1.72 vs $-1.54
Surprise
-11.69%

SLGL news

All SLGL news

Sol-Gel Technologies peers

Health Care sector
SLGL peer companies
CompanyPrice% ChgMarket capCompare
WHWKWhitehawk Therapeutics Inc.3.07-1.60%$181.16Mvs SLGL
ADCTADC Therapeutics SA1.28-1.54%$180.05Mvs SLGL
NATRNature's Sunshine Products Inc.10.18+0.10%$176.41Mvs SLGL
VOGXVogenx Inc11.87-7.30%$176.33Mvs SLGL
RNACCartesian Therapeutics Inc.6.14+4.24%$187.29Mvs SLGL
SIGASIGA Technologies Inc.2.40-9.43%$172.45Mvs SLGL
TRDAEntrada Therapeutics Inc.4.35-6.25%$170.30Mvs SLGL
ANTXAN2 Therapeutics Inc.5.08-2.68%$192.75Mvs SLGL

Indexes, lists and sector

Sol-Gel Technologies stock FAQ

What is Sol-Gel Technologies's stock price today?

SLGL last traded at $55.17 as of Nov 20, 4:00 PM EST, up 2.02% on the day. Prices are delayed at least 15 minutes.

Does Sol-Gel Technologies pay a dividend?

No. Sol-Gel Technologies does not currently pay a regular cash dividend.

Who is Sol-Gel Technologies's CEO?

Mr. Moshe Arkin is the chief executive officer of Sol-Gel Technologies Ltd., which has about 28 employees.

Has SLGL ever split its stock?

Yes. The most recent SLGL stock split was a 1-for-10 split on May 5, 2025.

What is the SLGL 52-week high?

The 52-week high for SLGL is $97.97 and the 52-week low is $34.47. The stock is currently 43.7% below its high.

Compare SLGL